Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Izumi Sato is active.

Publication


Featured researches published by Izumi Sato.


Acta Psychiatrica Scandinavica | 2017

International trends in clozapine use: a study in 17 countries

Christian J. Bachmann; Lise Aagaard; Miguel Bernardo; Lena Brandt; M. Cartabia; Antonio Clavenna; A. Coma Fusté; Kari Furu; Kristina Garuoliene; Falk Hoffmann; Samantha Hollingworth; Krista F. Huybrechts; Luuk J. Kalverdijk; Koji Kawakami; Helle Kieler; Takuya Kinoshita; S. C. López; Jorge Enrique Machado-Alba; Manuel Enrique Machado-Duque; Mufaddal Mahesri; Prasad S. Nishtala; D. Piovani; Johan Reutfors; Leena K. Saastamoinen; Izumi Sato; Catharina C.M. Schuiling-Veninga; Yu Chiau Shyu; Dan Siskind; Svetlana Skurtveit; Hélène Verdoux

There is some evidence that clozapine is significantly underutilised. Also, clozapine use is thought to vary by country, but so far no international study has assessed trends in clozapine prescribing. Therefore, this study aimed to assess clozapine use trends on an international scale, using standardised criteria for data analysis.


European Neuropsychopharmacology | 2017

International trends in antipsychotic use : A study in 16 countries, 2005-2014

Óskar Ö. Hálfdánarson; Helga Zoega; Lise Aagaard; Miquel Bernardo; Lena Brandt; Anna Coma Fusté; Kari Furu; Kristina Garuoliene; Falk Hoffmann; Krista F. Huybrechts; Luuk J. Kalverdijk; Koji Kawakami; Helle Kieler; Takuya Kinoshita; Melisa Litchfield; Soffy C. López; Jorge Enrique Machado-Alba; Manuel Enrique Machado-Duque; Mufaddal Mahesri; Prasad S. Nishtala; Sallie-Anne Pearson; Johan Reutfors; Leena K. Saastamoinen; Izumi Sato; Catharina C.M. Schuiling-Veninga; Yu Chiau Shyu; Svetlana Skurtveit; Hélène Verdoux; Liang-Jen Wang; Corinne Zara Yahni

The objective of this study was to assess international trends in antipsychotic use, using a standardised methodology. A repeated cross-sectional design was applied to data extracts from the years 2005 to 2014 from 16 countries worldwide. During the study period, the overall prevalence of antipsychotic use increased in 10 of the 16 studied countries. In 2014, the overall prevalence of antipsychotic use was highest in Taiwan (78.2/1000 persons), and lowest in Colombia (3.2/1000). In children and adolescents (0-19 years), antipsychotic use ranged from 0.5/1000 (Lithuania) to 30.8/1000 (Taiwan). In adults (20-64 years), the range was 2.8/1000 (Colombia) to 78.9/1000 (publicly insured US population), and in older adults (65+ years), antipsychotic use ranged from 19.0/1000 (Colombia) to 149.0/1000 (Taiwan). Atypical antipsychotic use increased in all populations (range of atypical/typical ratio: 0.7 (Taiwan) to 6.1 (New Zealand, Australia)). Quetiapine, risperidone, and olanzapine were most frequently prescribed. Prevalence and patterns of antipsychotic use varied markedly between countries. In the majority of populations, antipsychotic utilisation and especially the use of atypical antipsychotics increased over time. The high rates of antipsychotic prescriptions in older adults and in youths in some countries merit further investigation and systematic pharmacoepidemiologic monitoring.


Hepatology Research | 2015

Efficacy and safety of interferon treatment in elderly patients with chronic hepatitis C in Japan: A retrospective study using the Japanese Interferon Database

Izumi Sato; Takuro Shimbo; Yohei Kawasaki; Masashi Mizokami; Naohiko Masaki

Although interferon (IFN) treatment in elderly patients with chronic hepatitis C virus (HCV) infection has increased with the aging Japanese population, few studies have examined the efficacy and safety of IFN treatment in this population. We investigated the efficacy and safety of IFN treatment in elderly patients with chronic HCV infection using the Japanese Interferon Database.


Biopreservation and Biobanking | 2016

Clinical Data Interchange Standards Consortium Standardization of Biobank Data: A Feasibility Study

Izumi Sato; Yohei Kawasaki; Kazuki Ide; Iori Sakakibara; Keiko Konomura; Hiroshi Yamada; Yasuhiro Tanaka

The National Center Biobank Network (NCBN), consisting of six national centers (NCs) for advanced and specialized medical care, was launched in Japan in 2012 to collect biological specimens and health-related data. The common data formats of the six NCs, however, are not widely known outside the NCs. Therefore, we investigated whether the data elements collected by the NCBN could be made to conform to the international standards of the Clinical Data Interchange Standards Consortium (CDISC). We attempted to map the NCBN data elements (202 items) onto the Study Data Tabulation Model (SDTM), a set of CDISC standards on the submission format of electronic clinical data approved by the Food and Drug Administration. The results showed that all 202 items of the NCBN data could be mapped onto the SDTM and fulfilled 50%-70% of the required items of each domain specified in the SDTM. We concluded that, while the standardization of biobank data according to the CDISC standards is possible, there is a need to consider whether additional items must be included in the NCBN and to have experts familiar with the CDISC standards review the standardization needs.


Supportive Care in Cancer | 2017

Importance of eliminating potential dental focal infection before the first cycle of chemotherapy in patients with hematologic malignancy

Yasuyuki Shimada; Yumiko Nakagawa; Kazuki Ide; Izumi Sato; Shotaro Hagiwara; Hiroshi Yamada; Yohei Kawasaki; Yutaka Maruoka

Letter to the Editor, The oral cavity is a potential infection site in patients undergoing immunosuppressive therapy [1]. These patients are more susceptible to systemic infection, particularly those who need chemotherapy for hematologic malignancies [2]. Many dentists find it difficult to select an approach for dental focal infection in these patients [1, 2]. Although there is some literature assessing oral health in patients undergoing chemotherapy or pre-hematopoietic stem cell transplantation [3], these patients had already experienced adverse effects of chemotherapy, making it difficult to interpret the effect of dental treatment. Tooth extraction is a common surgical procedure performed to eliminate dental focal infection, and it carries a risk of perioperative surgical site infection (SSI) [1]. Although the frequency of tooth extraction-associated SSI is <5% in healthy individuals [4], it may be increased in patients with hematologic malignancy. We retrospectively reviewed the records of 160 patients with hematologic malignancy who visited the Department of Oral and Maxillofacial Surgery, Center Hospital, National Center for Global Health and Medicine, Tokyo, Japan, over a 2-year period to clarify the incidence of oral adverse events if dental problems are treated before the first chemotherapy cycle. Seventy-five patients were treated before the first cycle. Dental treatments were performed, and oral health status was assessed after chemotherapy. The observation period was the number of days from the start of the first chemotherapy cycle to just before the start of the second cycle. In cases where the cycle was unclear (e.g., when a single agent was administered repeatedly), the observation period was 30 days from chemotherapy initiation (i.e., the period deemed by hospital management to constitute adequate follow-up). Nine (12.0%) patients experienced oral adverse events after chemotherapy. No significant difference was found between the groups with and without tooth extraction (P = 0.28). The most frequently observed symptom was periodontitis aggravation (n = 3, 33.0%). Although all three patients were deemed to require extraction at the first stomatognathic screening, a decision not to proceed was made in two cases owing to a tight chemotherapy schedule. However, inflammation steadily worsened thereafter. Remarkably, only two of 28 (7.1%) tooth extraction cases had a poor outcome, regardless of the operative stress (surgical or simple extraction). Oral antibiotics (penicillin or cephem) were administered starting just after surgery in all extraction cases and continued at least for 3 days. If oral administration was impossible, the intravenous route was used. The median (min-max) white blood cell * Yasuyuki Shimada [email protected]


Pharmacoepidemiology and Drug Safety | 2017

Trends in antipsychotic prescriptions for Japanese outpatients during 2006–2012: a descriptive epidemiological study

Kenji Kochi; Izumi Sato; Chika Nishiyama; Sachiko Tanaka-Mizuno; Yuko Doi; Masaru Arai; Yosuke Fujii; Toshiyuki Matsunaga; Yusuke Ogawa; Toshi A. Furukawa; Koji Kawakami

This study aimed to assess the trends in antipsychotic prescriptions for outpatients in Japan, where a community‐based approach to mental healthcare is emphasized.


European Journal of Neurology | 2017

Diabetes mellitus and risk of early‐onset Alzheimer's disease: a population‐based case–control study

K. Kadohara; Izumi Sato; Koji Kawakami

Previous studies have reported that diabetes is a risk factor for both all‐cause and vascular dementia; however, diabetes as a risk factor for Alzheimers disease (AD) remains controversial. Therefore, the aim was to elucidate the association between diabetes and early‐onset AD.


PLOS ONE | 2016

Factors Influencing the Placebo Effect in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: An Analysis of Two Randomized Clinical Trials

Taichi Kawamura; Izumi Sato; Koji Kawakami

Objective To explore factors related to the placebo effect in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OH). Methods This was a retrospective cohort study of patients with POAG and patients with OH who were treated with placebo. The patients’ data were extracted from two randomized, double-masked, parallel, multicenter clinical trials (trial 1 and trial 2) in Japan. We explored the baseline factors that were associated with the intraocular pressure (IOP)-lowering effect of placebo ophthalmic solution after 4 weeks of instillation treatment at two time points by using multivariable models. The time points were Hour 0 (between 08:30 and 10:30 before instillation) and Hour 2 (within 1.5 to 2.5 h after instillation and by 12:30) at the baseline date and after 4 weeks. The changes in IOP from baseline to 4 weeks at the two time points were evaluated for the IOP-lowering effect induced by placebo instillation. Results Of the 330 patients included in the two trials, 89 patients were eligible for the analysis. The results of the multivariable analysis for Hour 0 indicated a high IOP at the baseline date (coefficient: 0.24, 95% confidence interval (CI): 0.02 to 0.46, P = 0.03), and the magnitude of the IOP fluctuation at the baseline date (coefficient: 0.57, 95% CI: 0.24 to 0.90, P = 0.001) was associated with the IOP-lowering effect after 4 weeks. With respect to Hour 2, the trial type was associated with the IOP-lowering effect (coefficient: -1.15, 95% CI: -2.14 to -0.16, P = 0.02). Conclusions A large fluctuation in IOP during the day is associated with the IOP-lowering effect induced by placebo in patients with POAG or OH. This finding would be helpful to researchers when designing studies related to glaucoma in the early stages of clinical development of drugs.


British Journal of Ophthalmology | 2017

Predictive factors for the placebo effect in clinical trials for dry eye: a pooled analysis of three clinical trials

Takahiro Imanaka; Izumi Sato; Shiro Tanaka; Koji Kawakami

Background Placebo effect is one of the methodological difficulties in dry eye clinical trials. If we could elucidate the tendencies of the placebo response and find predictors, we could reduce the placebo response in clinical trials for dry eye. In this study, we investigated the predictive factors for the placebo effect in dry eye clinical trials. Methods A total of 205 patients with dry eye assigned to the placebo arms of three placebo-controlled randomised clinical trials were analysed by simple and multivariable regression analysis. The corneal fluorescein (FL) staining score and dry eye symptoms were studied at week 4. The variables of interest included gender, age, complications of Sjögren’s syndrome, Schirmer’s test I value, tear break-up time and conjunctival hyperaemia score. We also conducted a stratified analysis according to the patients’ age. Results Among all the studied endpoints, the baseline scores were significantly related to the corresponding placebo response. In addition, for the FL score and the dryness score, age was a significant predictor of the placebo response (p=0.04 and p<0.0001, respectively). Stratified analysis by age showed that patients more than 40 years of age are more likely to have a stronger placebo response in the FL and dryness scores. Conclusion The baseline scores and age were predictive factors of the placebo response in frequently used endpoints, such as FL score or dryness symptoms. These patient characteristics can be controlled by study design, and our findings enable the design of more efficient placebo-controlled studies with good statistical power.


Psycho-oncology | 2018

Prevalence and initial prescription of psychotropics in patients with common cancers in Japan, based on a nationwide health insurance claims database

Izumi Sato; Hideki Onishi; Shuhei Yamada; Koji Kawakami

To investigate the prevalence of psychotropic medication use and identify factors affecting the prescription of psychotropics among patients newly diagnosed with any of 8 common types of cancer.

Collaboration


Dive into the Izumi Sato's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Hideki Onishi

Saitama Medical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge